+Follow
lebatsirhc
No personal profile
6
Follow
1
Followers
0
Topic
0
Badge
Posts
Hot
lebatsirhc
2021-09-03
Great ariticle, would you like to share it?
3 Hypergrowth Stocks Expected to Increase Sales 1,185% to 12,629% by 2023
lebatsirhc
2021-08-26
Great ariticle, would you like to share it?
4 Growth Stocks With 116% to 247% Upside, According to Wall Street
lebatsirhc
2021-05-28
Great ariticle, would you like to share it?
Sorry, the original content has been removed
lebatsirhc
2021-05-27
Great ariticle, would you like to share it?
Sorry, the original content has been removed
lebatsirhc
2021-05-11
$NIO Inc.(NIO)$
like if you're gonna hold through
lebatsirhc
2021-05-04
Great ariticle, would you like to share it?
Sorry, the original content has been removed
lebatsirhc
2021-04-25
Great ariticle, would you like to share it?
Sorry, the original content has been removed
lebatsirhc
2021-04-22
Great ariticle, would you like to share it?
Sorry, the original content has been removed
lebatsirhc
2021-04-20
Wow
Sorry, the original content has been removed
lebatsirhc
2021-04-19
$Nano Dimension(NNDM)$
Like if you're still holding
lebatsirhc
2021-04-19
Great ariticle, would you like to share it?
Sorry, the original content has been removed
lebatsirhc
2021-03-30
$Nano Dimension(NNDM)$
see you in 5 years
lebatsirhc
2021-03-17
Great ariticle, would you like to share it?
Sorry, the original content has been removed
lebatsirhc
2021-03-12
Ohh nice
Sorry, the original content has been removed
lebatsirhc
2021-03-12
$Nano Dimension(NNDM)$
It's finally going up! A good long hold
lebatsirhc
2021-03-10
$SOS Limited(SOS)$
Its gonna fly up, hang on tight guys!
lebatsirhc
2021-03-09
$NIO Inc.(NIO)$
Fundamentals of the company has not changed
lebatsirhc
2021-03-05
Average down!
Sorry, the original content has been removed
lebatsirhc
2021-03-05
At a loss but holding
Sorry, the original content has been removed
lebatsirhc
2021-03-05
Great ariticle, would you like to share it?
Sorry, the original content has been removed
Go to Tiger App to see more news
Invest in Global Markets with Tiger Brokers!
Open App
{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3562201797869028","uuid":"3562201797869028","gmtCreate":1599107775201,"gmtModify":1619447741432,"name":"lebatsirhc","pinyin":"lebatsirhc","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/3cfcaf13a73e3cf5792c54a3337d2315","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":6,"tweetSize":34,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.10.25","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.71%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"80.79%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":815597051,"gmtCreate":1630687082573,"gmtModify":1676530377605,"author":{"id":"3562201797869028","authorId":"3562201797869028","name":"lebatsirhc","avatar":"https://static.tigerbbs.com/3cfcaf13a73e3cf5792c54a3337d2315","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3562201797869028","idStr":"3562201797869028"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/815597051","repostId":"2164879370","repostType":4,"repost":{"id":"2164879370","kind":"highlight","pubTimestamp":1630678680,"share":"https://ttm.financial/m/news/2164879370?lang=&edition=full_marsco","pubTime":"2021-09-03 22:18","market":"us","language":"en","title":"3 Hypergrowth Stocks Expected to Increase Sales 1,185% to 12,629% by 2023","url":"https://stock-news.laohu8.com/highlight/detail?id=2164879370","media":"Motley Fool","summary":"These fast-paced companies should generate jaw-dropping revenue growth over the next three years.","content":"<p>Since the end of the Great Recession in 2009, growth stocks have thrived. Historically low lending rates, an ongoing quantitative easing program designed to weigh down long-term bond yields, and a free-spending Congress have all helped to make cheap capital widely abundant for businesses. This is helping to fuel acquisitions, hiring, and (most importantly) innovation.</p>\n<p>Yet for some companies, their exponential growth is just beginning. For each of the following hypergrowth stocks, Wall Street's consensus sales estimate for 2023, courtesy of <b>FactSet</b>, implies a revenue increase ranging from a low of 1,185% (yes, <i>a low of 1,185%</i>) to a high of 12,629%, compared to 2020 sales.</p>\n<h2>Moderna: Implied sales increase of 1,185%</h2>\n<p>Arguably the best-known name on this list is biotech <b>Moderna</b> (NASDAQ:MRNA). According to Wall Street, Moderna's annual revenue is expected to catapult from the $803.4 million recorded in 2020 to an estimated $10.33 billion in 2023. Interestingly, the $10.33 billion in projected sales for 2023 is about half of the $20.13 billion forecast this year.</p>\n<p>As a lot of you probably know, Modena's success is tied to the development of its coronavirus vaccine mRNA-1273. When the company ran a large-scale study of its COVID-19 vaccine, the results (released in November) demonstrated a vaccine efficacy (VE) of 94% and a strong propensity to keep vaccinated individuals from getting severe forms of the disease. This initial VE made Moderna's COVID vaccine a slam dunk for Emergency Use Authorization in the United States.</p>\n<p>When the company announced its second-quarter operating results on Aug. 5, it stuck to its original forecast of delivering between 800 million and 1 billion doses in 2021, with net product sales of around $20 billion. Next year, Moderna believes it can provide between 2 billion and 3 billion doses. As a reminder, the Moderna vaccine is a two-dose regimen, meaning its 2022 output could fully inoculate 1 billion to 1.5 billion people.</p>\n<p>Also working in Modena's favor is the possibility of booster vaccinations. The mutability of COVID, coupled with a handful of studies suggesting that VE begins waning at the six-month mark, could create a recurring vaccination need globally.</p>\n<p>While Moderna might sound like a surefire growth story, there are still big question marks about its future. For example, even though mRNA-1273 has been wildly successful, it's the only therapy that's generating sales for the company. Moderna's non-COVID pipeline looks to be years away from bringing in meaningful revenue.</p>\n<p>Equally concerning is the likelihood that the COVID vaccine space is going to become crowded. At some point soon, <b>Novavax</b> should join the field with a formidable initial VE of about 90%. It is also working on a combination COVID/influenza vaccine, which would be a differentiator and game changer.</p>\n<p>Not to take anything away from what Moderna has done, but a $150 billion market cap for a company with a single therapy seems awfully risky.</p>\n<h2><a href=\"https://laohu8.com/S/ZGNX\">Zogenix</a>: Implied sales increase of 2,451%</h2>\n<p>Another biotech stock that's expected to generate jaw-dropping sales growth through 2023 is small-cap <b>Zogenix</b> (NASDAQ:ZGNX). If Wall Street's consensus estimate proves accurate, the company's $13.64 million in reported sales in 2020 could grow to $348 million by 2023.</p>\n<p>Like Moderna, there's a single drug that looks to do all of the heavy lifting for Zogenix over the next couple of years: Fintepla. This is a drug targeted at a variety of seizure-related indications. It's already been approved by the Food and Drug Administration to treat Dravet syndrome. And Zogenix has plans to file a supplemental new drug application by the end of the current quarter to expand Fintepla's label to include Lennox-Gastaut syndrome (LGS). Both Dravet and LGS are rare forms of childhood-onset epilepsy. If approved, Zogenix could launch Fintepla for LGS patients in this country by as early as the first half of 2022.</p>\n<p>And Zogenix still isn't done with Fintepla. After hashing out the finer points with the FDA, the company intends to initiate a phase 3 study involving Fintepla as a treatment for CDKL5 deficiency disorder before the end of the year. Thus, organic growth and label expansion opportunities are expected to fuel sales of Fintepla to almost $350 million in three years.</p>\n<p>What'll be particularly interesting is how Zogenix fares against cannabinoid-focused drug developer GW Pharmaceuticals, which was acquired by <b>Jazz Pharmaceuticals</b> (NASDAQ:JAZZ) in May. GW's lead drug, Epidiolex, is a cannabidiol-based treatment that's been approved by the FDA to treat Dravet syndrome and LGS, and it launched in advance of Zogenix's Fintepla. For comparative purposes, Jazz announced that Epidiolex brought home $155.9 million in sales just in the second quarter, although it has an additional indication under its belt (tuberous sclerosis complex) where it won't compete against Zogenix.</p>\n<p>Although Epidiolex appears to have the upper hand now, it's worth noting that seizure-reduction efficacy for Fintepla looked very promising in late-stage clinical trials. To be 100% clear, the GW Pharma and Zogenix studies were never pitted head-to-head, and their baseline parameters are different. Nevertheless, Fintepla led to a 62.3% reduction in mean monthly convulsive seizure frequency compared to placebo at the six-week mark for Dravet syndrome patients.</p>\n<p>Comparatively, Jazz's Epidiolex demonstrated reductions in seizure frequency from baseline of 56% and 47%, respectively, for the lower- and higher-dose treatments in phase 3 studies in Dravet syndrome patients. Suffice it to say, these could be highly competitive indications for the foreseeable future.</p>\n<h2>Marathon Digital Holdings: Implied sales increase of 12,629%</h2>\n<p>Now, if you want pedal-to-the-metal growth, look no further than <b>Marathon Digital Holdings</b> (NASDAQ:MARA). After reporting a meager $4.36 million in sales in 2020, Wall Street anticipates full-year sales will climb to $555 million by 2023. That's an increase of 12,629%.</p>\n<p>If you're wondering how sales growth of this magnitude is possible for a company not involved in drug development, look no further than cryptocurrencies.</p>\n<p>Marathon Digital is a cryptocurrency mining company. It operates a farm of high-powered computing devices designed to solve complex mathematical equations that validate groups of transactions (known as a block) as valid on a digital currency's blockchain. For being the first to validate a block, Marathon is paid a block reward. This reward is typically a set amount of digital tokens from the digital currency being mined.</p>\n<p>In Marathon's case, it's mining <b>Bitcoin</b> (CRYPTO:BTC), the largest cryptocurrency in the world by market cap. Being the first to mine a Bitcoin block results in the company being awarded 6.25 Bitcoin tokens, which were worth a cool $292,000, as of Aug. 30.</p>\n<p>The reason Marathon's sales are skyrocketing so quickly is because it's in the midst of deploying <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the largest Bitcoin-mining operations in the United States. As of the beginning of August, approximately 30,100 miners were operating, with another 103,000 ordered and yet to be installed. By the end of the first quarter of 2022, Marathon should have north of 100,000 miners in operation, with all 133,120 up and running by July 2022.</p>\n<p>Though Marathon is the fastest-growing of these three hypergrowth stocks, it's also arguably the most dangerous investment of this trio. That's because it's entirely dependent on external factors, such as interest in, and the price of, Bitcoin -- and not innovation.</p>\n<p>What's more, the barrier to entry in the cryptocurrency mining space is virtually nonexistent. As time passes, it's going to be tougher for Marathon to successfully mine Bitcoin.</p>\n<p>As the icing on the cake, Bitcoin's block rewards halve every four years. By 2024, only 3.125 Bitcoin tokens will be paid for validating a block. Essentially, Marathon is competing against a growing number of mining companies for a reward that's shrinking. It simply doesn't sound like an operating model with long-term staying power.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Hypergrowth Stocks Expected to Increase Sales 1,185% to 12,629% by 2023</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Hypergrowth Stocks Expected to Increase Sales 1,185% to 12,629% by 2023\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-03 22:18 GMT+8 <a href=https://www.fool.com/investing/2021/09/03/3-hypergrowth-stocks-increase-sales-1185-to-12629/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Since the end of the Great Recession in 2009, growth stocks have thrived. Historically low lending rates, an ongoing quantitative easing program designed to weigh down long-term bond yields, and a ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/03/3-hypergrowth-stocks-increase-sales-1185-to-12629/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ZGNX":"Zogenix","MARA":"MARA Holdings","MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/09/03/3-hypergrowth-stocks-increase-sales-1185-to-12629/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2164879370","content_text":"Since the end of the Great Recession in 2009, growth stocks have thrived. Historically low lending rates, an ongoing quantitative easing program designed to weigh down long-term bond yields, and a free-spending Congress have all helped to make cheap capital widely abundant for businesses. This is helping to fuel acquisitions, hiring, and (most importantly) innovation.\nYet for some companies, their exponential growth is just beginning. For each of the following hypergrowth stocks, Wall Street's consensus sales estimate for 2023, courtesy of FactSet, implies a revenue increase ranging from a low of 1,185% (yes, a low of 1,185%) to a high of 12,629%, compared to 2020 sales.\nModerna: Implied sales increase of 1,185%\nArguably the best-known name on this list is biotech Moderna (NASDAQ:MRNA). According to Wall Street, Moderna's annual revenue is expected to catapult from the $803.4 million recorded in 2020 to an estimated $10.33 billion in 2023. Interestingly, the $10.33 billion in projected sales for 2023 is about half of the $20.13 billion forecast this year.\nAs a lot of you probably know, Modena's success is tied to the development of its coronavirus vaccine mRNA-1273. When the company ran a large-scale study of its COVID-19 vaccine, the results (released in November) demonstrated a vaccine efficacy (VE) of 94% and a strong propensity to keep vaccinated individuals from getting severe forms of the disease. This initial VE made Moderna's COVID vaccine a slam dunk for Emergency Use Authorization in the United States.\nWhen the company announced its second-quarter operating results on Aug. 5, it stuck to its original forecast of delivering between 800 million and 1 billion doses in 2021, with net product sales of around $20 billion. Next year, Moderna believes it can provide between 2 billion and 3 billion doses. As a reminder, the Moderna vaccine is a two-dose regimen, meaning its 2022 output could fully inoculate 1 billion to 1.5 billion people.\nAlso working in Modena's favor is the possibility of booster vaccinations. The mutability of COVID, coupled with a handful of studies suggesting that VE begins waning at the six-month mark, could create a recurring vaccination need globally.\nWhile Moderna might sound like a surefire growth story, there are still big question marks about its future. For example, even though mRNA-1273 has been wildly successful, it's the only therapy that's generating sales for the company. Moderna's non-COVID pipeline looks to be years away from bringing in meaningful revenue.\nEqually concerning is the likelihood that the COVID vaccine space is going to become crowded. At some point soon, Novavax should join the field with a formidable initial VE of about 90%. It is also working on a combination COVID/influenza vaccine, which would be a differentiator and game changer.\nNot to take anything away from what Moderna has done, but a $150 billion market cap for a company with a single therapy seems awfully risky.\nZogenix: Implied sales increase of 2,451%\nAnother biotech stock that's expected to generate jaw-dropping sales growth through 2023 is small-cap Zogenix (NASDAQ:ZGNX). If Wall Street's consensus estimate proves accurate, the company's $13.64 million in reported sales in 2020 could grow to $348 million by 2023.\nLike Moderna, there's a single drug that looks to do all of the heavy lifting for Zogenix over the next couple of years: Fintepla. This is a drug targeted at a variety of seizure-related indications. It's already been approved by the Food and Drug Administration to treat Dravet syndrome. And Zogenix has plans to file a supplemental new drug application by the end of the current quarter to expand Fintepla's label to include Lennox-Gastaut syndrome (LGS). Both Dravet and LGS are rare forms of childhood-onset epilepsy. If approved, Zogenix could launch Fintepla for LGS patients in this country by as early as the first half of 2022.\nAnd Zogenix still isn't done with Fintepla. After hashing out the finer points with the FDA, the company intends to initiate a phase 3 study involving Fintepla as a treatment for CDKL5 deficiency disorder before the end of the year. Thus, organic growth and label expansion opportunities are expected to fuel sales of Fintepla to almost $350 million in three years.\nWhat'll be particularly interesting is how Zogenix fares against cannabinoid-focused drug developer GW Pharmaceuticals, which was acquired by Jazz Pharmaceuticals (NASDAQ:JAZZ) in May. GW's lead drug, Epidiolex, is a cannabidiol-based treatment that's been approved by the FDA to treat Dravet syndrome and LGS, and it launched in advance of Zogenix's Fintepla. For comparative purposes, Jazz announced that Epidiolex brought home $155.9 million in sales just in the second quarter, although it has an additional indication under its belt (tuberous sclerosis complex) where it won't compete against Zogenix.\nAlthough Epidiolex appears to have the upper hand now, it's worth noting that seizure-reduction efficacy for Fintepla looked very promising in late-stage clinical trials. To be 100% clear, the GW Pharma and Zogenix studies were never pitted head-to-head, and their baseline parameters are different. Nevertheless, Fintepla led to a 62.3% reduction in mean monthly convulsive seizure frequency compared to placebo at the six-week mark for Dravet syndrome patients.\nComparatively, Jazz's Epidiolex demonstrated reductions in seizure frequency from baseline of 56% and 47%, respectively, for the lower- and higher-dose treatments in phase 3 studies in Dravet syndrome patients. Suffice it to say, these could be highly competitive indications for the foreseeable future.\nMarathon Digital Holdings: Implied sales increase of 12,629%\nNow, if you want pedal-to-the-metal growth, look no further than Marathon Digital Holdings (NASDAQ:MARA). After reporting a meager $4.36 million in sales in 2020, Wall Street anticipates full-year sales will climb to $555 million by 2023. That's an increase of 12,629%.\nIf you're wondering how sales growth of this magnitude is possible for a company not involved in drug development, look no further than cryptocurrencies.\nMarathon Digital is a cryptocurrency mining company. It operates a farm of high-powered computing devices designed to solve complex mathematical equations that validate groups of transactions (known as a block) as valid on a digital currency's blockchain. For being the first to validate a block, Marathon is paid a block reward. This reward is typically a set amount of digital tokens from the digital currency being mined.\nIn Marathon's case, it's mining Bitcoin (CRYPTO:BTC), the largest cryptocurrency in the world by market cap. Being the first to mine a Bitcoin block results in the company being awarded 6.25 Bitcoin tokens, which were worth a cool $292,000, as of Aug. 30.\nThe reason Marathon's sales are skyrocketing so quickly is because it's in the midst of deploying one of the largest Bitcoin-mining operations in the United States. As of the beginning of August, approximately 30,100 miners were operating, with another 103,000 ordered and yet to be installed. By the end of the first quarter of 2022, Marathon should have north of 100,000 miners in operation, with all 133,120 up and running by July 2022.\nThough Marathon is the fastest-growing of these three hypergrowth stocks, it's also arguably the most dangerous investment of this trio. That's because it's entirely dependent on external factors, such as interest in, and the price of, Bitcoin -- and not innovation.\nWhat's more, the barrier to entry in the cryptocurrency mining space is virtually nonexistent. As time passes, it's going to be tougher for Marathon to successfully mine Bitcoin.\nAs the icing on the cake, Bitcoin's block rewards halve every four years. By 2024, only 3.125 Bitcoin tokens will be paid for validating a block. Essentially, Marathon is competing against a growing number of mining companies for a reward that's shrinking. It simply doesn't sound like an operating model with long-term staying power.","news_type":1},"isVote":1,"tweetType":1,"viewCount":429,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":810442478,"gmtCreate":1629997599494,"gmtModify":1676530197097,"author":{"id":"3562201797869028","authorId":"3562201797869028","name":"lebatsirhc","avatar":"https://static.tigerbbs.com/3cfcaf13a73e3cf5792c54a3337d2315","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3562201797869028","idStr":"3562201797869028"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/810442478","repostId":"2162931260","repostType":4,"repost":{"id":"2162931260","kind":"highlight","pubTimestamp":1629982994,"share":"https://ttm.financial/m/news/2162931260?lang=&edition=full_marsco","pubTime":"2021-08-26 21:03","market":"us","language":"en","title":"4 Growth Stocks With 116% to 247% Upside, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2162931260","media":"Motley Fool","summary":"Analysts' high-water price targets foresee these fast-growing stocks doubling or tripling in value.","content":"<p>Patience has paid off handsomely for investors in 2021. It's been over nine months since the benchmark <b>S&P 500</b> underwent even a 5% correction. Panning out a bit further, the widely followed index has doubled since hitting its bear-market low on March 23, 2020.</p>\n<p>Yet, even with the stock market mowing down record highs on a regular basis this year, Wall Street still sees value in a number of growth stocks. Based on the highest price target issued by a Wall Street analyst or investment bank, the following four growth stocks could deliver gains ranging from 116% to as much as 247%.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F640299%2Fbull-market-rising-stock-chart-economy-bear-newspaper-getty.jpg&w=700&op=resize\" tg-width=\"700\" tg-height=\"525\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Tesla Motors: Implied upside of 134%</h2>\n<p>Few stocks are as polarizing on Wall Street, from the perspective of price targets, than electric vehicle (EV) company <b>Tesla Motors</b> (NASDAQ:TSLA). Whereas <a href=\"https://laohu8.com/S/AONE.U\">one</a> analyst foresees approximately 90% downside in shares of the company, another believes Tesla could \"motor\" its way to $1,591 a share. This would represent 134% upside from where the company ended this past week.</p>\n<p>On one hand, Tesla has clear-cut advantages that are driving it forward. For instance, its battery technology offers more capacity, range, and power than competing EV manufacturers. Tesla has also built itself from the ground up to mass production. Based on its second-quarter deliveries of 201,250, the company looks to be on its way to topping 1 million annual deliveries by as soon as next year. Finally, don't overlook that Tesla has visionary Elon Musk as its CEO.</p>\n<p>On the other hand, it's unlikely that Tesla will be able to hang onto its competitive edges over the long run, with auto stocks like <b>Ford Motor Company</b> and <b>General Motors</b> respectively investing $30 billion and $35 billion through mid-decade in EVs and related technology. Both companies plan to respectively launch 30 new EVs globally by 2025.</p>\n<p>Perhaps the biggest concern is that Tesla hadn't generated a true operating profit until the latest quarter. Though it's been profitable for more than a year, the company had relied on selling renewable energy credits and one-time asset sales (e.g., <b>Bitcoin</b>) to generate a profit. If Tesla is ever going to hit $1,591 a share, its EV sales, not one-time benefits, will have to do the talking.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F640299%2Fmarijuana-cannabis-oil-pot-weed-leaf-drug-medical-getty.jpg&w=700&op=resize\" tg-width=\"700\" tg-height=\"568\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Green Thumb Industries: Implied upside of 116%</h2>\n<p>Wall Street also sees U.S. marijuana stocks budding over the coming year. In particular, one Wall Street analyst believes multistate operator (MSO) <b>Green Thumb Industries</b> (OTC:GTBIF) can rally to north of $61 a share, which would equate to 116% implied upside.</p>\n<p>The great thing for U.S. MSOs is that they don't need federal reform to thrive. We've watched 36 states legalize cannabis in some capacity, which is providing more than enough of a growth opportunity for MSOs and ancillary players to succeed. By mid-decade, <a href=\"https://laohu8.com/S/NFC.U\">New Frontier</a> Data is predicting that the U.S. weed industry could bring in $41.5 billion in annual sales.</p>\n<p>Green Thumb currently has 62 operating dispensaries, with 111 total retail licenses in its back pocket and a presence in 14 states. This is a company that's been picky about its expansion and has generally focused on either high-dollar states or markets protected by limited license issuance. In Illinois, for instance, the number of retail licenses issued, in total and to a single business, is capped. This should give Green Thumb a good opportunity to gobble up market share in a billion-dollar market.</p>\n<p>But the best aspect of Green Thumb is arguably its product mix. A majority of the company's sales come from derivatives, such as vapes, edibles, and infused beverages. Since derivatives generate higher margins than dried cannabis flower and are less likely to face supply issues, they're the reason Green Thumb has been profitable on a recurring basis for the past year. In other words, Wall Street's most aggressive price target may become a reality.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/69c8d46ab082fe9b933b958f3354a003\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Skillz: Implied upside of 138%</h2>\n<p>Another high-growth stock at least one Wall Street analyst believes could soar is mobile gaming platform <b>Skillz</b> (NYSE:SKLZ). With a high-water price target of $25, the implication is that Skillz could return up to 138% for its shareholders over the next year.</p>\n<p>To be upfront, Skillz has performed very poorly of late. It's lost more than three-quarters of its value since early February, which is a reflection of the company's operating losses expanding. Skillz has been increasing its headcount, marketing to expand its reach, and making acquisitions. This all points to ongoing operating losses for the foreseeable future.</p>\n<p>However, there's no denying the potential for this company, either. During the first quarter, approximately 17% of its monthly active users were paying to play on its platform, which is substantially higher than the industry conversion average of around 2%. Furthermore, with Skillz acting as a middleman platform for gamers, its ongoing operating expenses (aside from marketing) are quite low. As a result, it's been consistently generating a gross margin of 95%.</p>\n<p>Probably the most exciting thing for Skillz is the multiyear agreement it signed with the National Football League (NFL) in February. Football is the most popular sport in the United States. The expectation is that NFL-themed games will hit its platform in 2022, which could bring in a number of new users and partnerships.</p>\n<p>While I do believe a $25 price target is possible, investors will need to exercise patience as Skillz focuses on expanding its brand.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F640299%2Fbiotech-lab-researcher-examining-test-tube-getty.jpg&w=700&op=resize\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Exelixis: Implied upside of 247%</h2>\n<p>But the crème de la crème of potential upside comes from biotech stock <b>Exelixis</b> (NASDAQ:EXEL). With investment firm HC Wainwright recently anointing Exelixis with a $64 price target, the implied upside for shareholders is an insane 247%, based on where it closed last week. In fact, Exelixis' share price is currently below all 13 issued Wall Street price targets.</p>\n<p>If you're looking for a reason behind Exelixis' relative \"cheapness\" to Wall Street's price targets, the company's late-June interim data release from the Cosmic-312 study holds the answer. While the ongoing phase 3 study of Exelixis' leading cancer drug, Cabometyx, in combination with atezolizumab demonstrated a statistically significant improvement in progression-free survival for previously untreated liver cancer patients, the data looked unlikely to produce a statistically significant survival benefit.</p>\n<p>Although this might sound like a disappointment, it's par for the course when developing cancer drugs. Thus far, Cabometyx has been approved as a treatment for first- and second-line renal cell carcinoma (RCC) and advanced hepatocellular carcinoma. These indications alone should push its annual sales past $1 billion in 2022.</p>\n<p>However, Cabometyx is being examined in around six dozen additional studies as a monotherapy or combination treatment. If even a handful of these trials succeed, label expansion opportunities could send Exelixis markedly higher. It's worth pointing out that one of these studies, CheckMate-9ER, already led the Food and Drug Administration to approve the combination of Cabometyx and <b>Bristol Myers Squibb</b>'s cancer immunotherapy Opdivo as a treatment for first-line RCC.</p>\n<p>With a hearty cash pile and plenty of long-term momentum for Cabometyx, Exelixis looks incredibly cheap. I'm not certain that $64 is in the cards, but higher than where it currently sits is the direction it's likely headed.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>4 Growth Stocks With 116% to 247% Upside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n4 Growth Stocks With 116% to 247% Upside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-26 21:03 GMT+8 <a href=https://www.fool.com/investing/2021/08/26/4-growth-stocks-with-116-to-247-upside-wall-street/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Patience has paid off handsomely for investors in 2021. It's been over nine months since the benchmark S&P 500 underwent even a 5% correction. Panning out a bit further, the widely followed index has ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/26/4-growth-stocks-with-116-to-247-upside-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SKLZ":"Skillz Inc","GTBIF":"Green Thumb Industries Inc.","TSLA":"特斯拉","EXEL":"伊克力西斯"},"source_url":"https://www.fool.com/investing/2021/08/26/4-growth-stocks-with-116-to-247-upside-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2162931260","content_text":"Patience has paid off handsomely for investors in 2021. It's been over nine months since the benchmark S&P 500 underwent even a 5% correction. Panning out a bit further, the widely followed index has doubled since hitting its bear-market low on March 23, 2020.\nYet, even with the stock market mowing down record highs on a regular basis this year, Wall Street still sees value in a number of growth stocks. Based on the highest price target issued by a Wall Street analyst or investment bank, the following four growth stocks could deliver gains ranging from 116% to as much as 247%.\nImage source: Getty Images.\nTesla Motors: Implied upside of 134%\nFew stocks are as polarizing on Wall Street, from the perspective of price targets, than electric vehicle (EV) company Tesla Motors (NASDAQ:TSLA). Whereas one analyst foresees approximately 90% downside in shares of the company, another believes Tesla could \"motor\" its way to $1,591 a share. This would represent 134% upside from where the company ended this past week.\nOn one hand, Tesla has clear-cut advantages that are driving it forward. For instance, its battery technology offers more capacity, range, and power than competing EV manufacturers. Tesla has also built itself from the ground up to mass production. Based on its second-quarter deliveries of 201,250, the company looks to be on its way to topping 1 million annual deliveries by as soon as next year. Finally, don't overlook that Tesla has visionary Elon Musk as its CEO.\nOn the other hand, it's unlikely that Tesla will be able to hang onto its competitive edges over the long run, with auto stocks like Ford Motor Company and General Motors respectively investing $30 billion and $35 billion through mid-decade in EVs and related technology. Both companies plan to respectively launch 30 new EVs globally by 2025.\nPerhaps the biggest concern is that Tesla hadn't generated a true operating profit until the latest quarter. Though it's been profitable for more than a year, the company had relied on selling renewable energy credits and one-time asset sales (e.g., Bitcoin) to generate a profit. If Tesla is ever going to hit $1,591 a share, its EV sales, not one-time benefits, will have to do the talking.\nImage source: Getty Images.\nGreen Thumb Industries: Implied upside of 116%\nWall Street also sees U.S. marijuana stocks budding over the coming year. In particular, one Wall Street analyst believes multistate operator (MSO) Green Thumb Industries (OTC:GTBIF) can rally to north of $61 a share, which would equate to 116% implied upside.\nThe great thing for U.S. MSOs is that they don't need federal reform to thrive. We've watched 36 states legalize cannabis in some capacity, which is providing more than enough of a growth opportunity for MSOs and ancillary players to succeed. By mid-decade, New Frontier Data is predicting that the U.S. weed industry could bring in $41.5 billion in annual sales.\nGreen Thumb currently has 62 operating dispensaries, with 111 total retail licenses in its back pocket and a presence in 14 states. This is a company that's been picky about its expansion and has generally focused on either high-dollar states or markets protected by limited license issuance. In Illinois, for instance, the number of retail licenses issued, in total and to a single business, is capped. This should give Green Thumb a good opportunity to gobble up market share in a billion-dollar market.\nBut the best aspect of Green Thumb is arguably its product mix. A majority of the company's sales come from derivatives, such as vapes, edibles, and infused beverages. Since derivatives generate higher margins than dried cannabis flower and are less likely to face supply issues, they're the reason Green Thumb has been profitable on a recurring basis for the past year. In other words, Wall Street's most aggressive price target may become a reality.\nImage source: Getty Images.\nSkillz: Implied upside of 138%\nAnother high-growth stock at least one Wall Street analyst believes could soar is mobile gaming platform Skillz (NYSE:SKLZ). With a high-water price target of $25, the implication is that Skillz could return up to 138% for its shareholders over the next year.\nTo be upfront, Skillz has performed very poorly of late. It's lost more than three-quarters of its value since early February, which is a reflection of the company's operating losses expanding. Skillz has been increasing its headcount, marketing to expand its reach, and making acquisitions. This all points to ongoing operating losses for the foreseeable future.\nHowever, there's no denying the potential for this company, either. During the first quarter, approximately 17% of its monthly active users were paying to play on its platform, which is substantially higher than the industry conversion average of around 2%. Furthermore, with Skillz acting as a middleman platform for gamers, its ongoing operating expenses (aside from marketing) are quite low. As a result, it's been consistently generating a gross margin of 95%.\nProbably the most exciting thing for Skillz is the multiyear agreement it signed with the National Football League (NFL) in February. Football is the most popular sport in the United States. The expectation is that NFL-themed games will hit its platform in 2022, which could bring in a number of new users and partnerships.\nWhile I do believe a $25 price target is possible, investors will need to exercise patience as Skillz focuses on expanding its brand.\nImage source: Getty Images.\nExelixis: Implied upside of 247%\nBut the crème de la crème of potential upside comes from biotech stock Exelixis (NASDAQ:EXEL). With investment firm HC Wainwright recently anointing Exelixis with a $64 price target, the implied upside for shareholders is an insane 247%, based on where it closed last week. In fact, Exelixis' share price is currently below all 13 issued Wall Street price targets.\nIf you're looking for a reason behind Exelixis' relative \"cheapness\" to Wall Street's price targets, the company's late-June interim data release from the Cosmic-312 study holds the answer. While the ongoing phase 3 study of Exelixis' leading cancer drug, Cabometyx, in combination with atezolizumab demonstrated a statistically significant improvement in progression-free survival for previously untreated liver cancer patients, the data looked unlikely to produce a statistically significant survival benefit.\nAlthough this might sound like a disappointment, it's par for the course when developing cancer drugs. Thus far, Cabometyx has been approved as a treatment for first- and second-line renal cell carcinoma (RCC) and advanced hepatocellular carcinoma. These indications alone should push its annual sales past $1 billion in 2022.\nHowever, Cabometyx is being examined in around six dozen additional studies as a monotherapy or combination treatment. If even a handful of these trials succeed, label expansion opportunities could send Exelixis markedly higher. It's worth pointing out that one of these studies, CheckMate-9ER, already led the Food and Drug Administration to approve the combination of Cabometyx and Bristol Myers Squibb's cancer immunotherapy Opdivo as a treatment for first-line RCC.\nWith a hearty cash pile and plenty of long-term momentum for Cabometyx, Exelixis looks incredibly cheap. I'm not certain that $64 is in the cards, but higher than where it currently sits is the direction it's likely headed.","news_type":1},"isVote":1,"tweetType":1,"viewCount":479,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":134887062,"gmtCreate":1622215957856,"gmtModify":1704181755331,"author":{"id":"3562201797869028","authorId":"3562201797869028","name":"lebatsirhc","avatar":"https://static.tigerbbs.com/3cfcaf13a73e3cf5792c54a3337d2315","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3562201797869028","idStr":"3562201797869028"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/134887062","repostId":"1170226387","repostType":4,"isVote":1,"tweetType":1,"viewCount":326,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":135364657,"gmtCreate":1622132645479,"gmtModify":1704180143155,"author":{"id":"3562201797869028","authorId":"3562201797869028","name":"lebatsirhc","avatar":"https://static.tigerbbs.com/3cfcaf13a73e3cf5792c54a3337d2315","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3562201797869028","idStr":"3562201797869028"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/135364657","repostId":"2138531112","repostType":4,"isVote":1,"tweetType":1,"viewCount":412,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":199732328,"gmtCreate":1620733316664,"gmtModify":1704347500670,"author":{"id":"3562201797869028","authorId":"3562201797869028","name":"lebatsirhc","avatar":"https://static.tigerbbs.com/3cfcaf13a73e3cf5792c54a3337d2315","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3562201797869028","idStr":"3562201797869028"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>like if you're gonna hold through","listText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>like if you're gonna hold through","text":"$NIO Inc.(NIO)$like if you're gonna hold through","images":[{"img":"https://static.tigerbbs.com/c1c7917136a0ac1b9421f0d6531ab349","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/199732328","isVote":1,"tweetType":1,"viewCount":418,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":106607516,"gmtCreate":1620107296135,"gmtModify":1704338768710,"author":{"id":"3562201797869028","authorId":"3562201797869028","name":"lebatsirhc","avatar":"https://static.tigerbbs.com/3cfcaf13a73e3cf5792c54a3337d2315","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3562201797869028","idStr":"3562201797869028"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/106607516","repostId":"1140379495","repostType":4,"isVote":1,"tweetType":1,"viewCount":202,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":375684433,"gmtCreate":1619333107922,"gmtModify":1704722598125,"author":{"id":"3562201797869028","authorId":"3562201797869028","name":"lebatsirhc","avatar":"https://static.tigerbbs.com/3cfcaf13a73e3cf5792c54a3337d2315","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3562201797869028","idStr":"3562201797869028"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/375684433","repostId":"2129365307","repostType":4,"isVote":1,"tweetType":1,"viewCount":434,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":376388297,"gmtCreate":1619089745719,"gmtModify":1704719458826,"author":{"id":"3562201797869028","authorId":"3562201797869028","name":"lebatsirhc","avatar":"https://static.tigerbbs.com/3cfcaf13a73e3cf5792c54a3337d2315","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3562201797869028","idStr":"3562201797869028"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/376388297","repostId":"2129938659","repostType":4,"isVote":1,"tweetType":1,"viewCount":389,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":371979638,"gmtCreate":1618906778324,"gmtModify":1704716664186,"author":{"id":"3562201797869028","authorId":"3562201797869028","name":"lebatsirhc","avatar":"https://static.tigerbbs.com/3cfcaf13a73e3cf5792c54a3337d2315","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3562201797869028","idStr":"3562201797869028"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/371979638","repostId":"1143900668","repostType":4,"isVote":1,"tweetType":1,"viewCount":383,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":373626144,"gmtCreate":1618843605888,"gmtModify":1704715799233,"author":{"id":"3562201797869028","authorId":"3562201797869028","name":"lebatsirhc","avatar":"https://static.tigerbbs.com/3cfcaf13a73e3cf5792c54a3337d2315","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3562201797869028","idStr":"3562201797869028"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NNDM\">$Nano Dimension(NNDM)$</a>Like if you're still holding","listText":"<a href=\"https://laohu8.com/S/NNDM\">$Nano Dimension(NNDM)$</a>Like if you're still holding","text":"$Nano Dimension(NNDM)$Like if you're still holding","images":[{"img":"https://static.tigerbbs.com/c6eb8290d836873ae5c6ece4cb072279","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":16,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/373626144","isVote":1,"tweetType":1,"viewCount":366,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":373335850,"gmtCreate":1618820768670,"gmtModify":1704715331474,"author":{"id":"3562201797869028","authorId":"3562201797869028","name":"lebatsirhc","avatar":"https://static.tigerbbs.com/3cfcaf13a73e3cf5792c54a3337d2315","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3562201797869028","idStr":"3562201797869028"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/373335850","repostId":"1131815435","repostType":4,"isVote":1,"tweetType":1,"viewCount":262,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":355732321,"gmtCreate":1617103824263,"gmtModify":1704695855931,"author":{"id":"3562201797869028","authorId":"3562201797869028","name":"lebatsirhc","avatar":"https://static.tigerbbs.com/3cfcaf13a73e3cf5792c54a3337d2315","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3562201797869028","idStr":"3562201797869028"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NNDM\">$Nano Dimension(NNDM)$</a>see you in 5 years","listText":"<a href=\"https://laohu8.com/S/NNDM\">$Nano Dimension(NNDM)$</a>see you in 5 years","text":"$Nano Dimension(NNDM)$see you in 5 years","images":[{"img":"https://static.tigerbbs.com/43cb66f9dc0c223d6dea5581184b5ed6","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/355732321","isVote":1,"tweetType":1,"viewCount":144,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":324301502,"gmtCreate":1615958536806,"gmtModify":1704788941699,"author":{"id":"3562201797869028","authorId":"3562201797869028","name":"lebatsirhc","avatar":"https://static.tigerbbs.com/3cfcaf13a73e3cf5792c54a3337d2315","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3562201797869028","idStr":"3562201797869028"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/324301502","repostId":"1107740379","repostType":4,"isVote":1,"tweetType":1,"viewCount":154,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":328227651,"gmtCreate":1615533356073,"gmtModify":1704784190685,"author":{"id":"3562201797869028","authorId":"3562201797869028","name":"lebatsirhc","avatar":"https://static.tigerbbs.com/3cfcaf13a73e3cf5792c54a3337d2315","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3562201797869028","idStr":"3562201797869028"},"themes":[],"htmlText":"Ohh nice","listText":"Ohh nice","text":"Ohh nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/328227651","repostId":"1199156489","repostType":4,"isVote":1,"tweetType":1,"viewCount":39,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":328632629,"gmtCreate":1615518640361,"gmtModify":1704783994211,"author":{"id":"3562201797869028","authorId":"3562201797869028","name":"lebatsirhc","avatar":"https://static.tigerbbs.com/3cfcaf13a73e3cf5792c54a3337d2315","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3562201797869028","idStr":"3562201797869028"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NNDM\">$Nano Dimension(NNDM)$</a>It's finally going up! A good long hold","listText":"<a href=\"https://laohu8.com/S/NNDM\">$Nano Dimension(NNDM)$</a>It's finally going up! A good long hold","text":"$Nano Dimension(NNDM)$It's finally going up! A good long hold","images":[{"img":"https://static.tigerbbs.com/6d2aa7e78496f244298e9a0eb7674f7c","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/328632629","isVote":1,"tweetType":1,"viewCount":116,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":321094765,"gmtCreate":1615383931257,"gmtModify":1704781958076,"author":{"id":"3562201797869028","authorId":"3562201797869028","name":"lebatsirhc","avatar":"https://static.tigerbbs.com/3cfcaf13a73e3cf5792c54a3337d2315","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3562201797869028","idStr":"3562201797869028"},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/SOS\">$SOS Limited(SOS)$</a> Its gonna fly up, hang on tight guys!","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/SOS\">$SOS Limited(SOS)$</a> Its gonna fly up, hang on tight guys!","text":"$SOS Limited(SOS)$ Its gonna fly up, hang on tight guys!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/321094765","isVote":1,"tweetType":1,"viewCount":44,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":329575317,"gmtCreate":1615263962939,"gmtModify":1704780303125,"author":{"id":"3562201797869028","authorId":"3562201797869028","name":"lebatsirhc","avatar":"https://static.tigerbbs.com/3cfcaf13a73e3cf5792c54a3337d2315","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3562201797869028","idStr":"3562201797869028"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>Fundamentals of the company has not changed","listText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>Fundamentals of the company has not changed","text":"$NIO Inc.(NIO)$Fundamentals of the company has not changed","images":[{"img":"https://static.tigerbbs.com/22398505ea945a7866c7a96be600c345","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/329575317","isVote":1,"tweetType":1,"viewCount":51,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":367619911,"gmtCreate":1614943365033,"gmtModify":1704777258017,"author":{"id":"3562201797869028","authorId":"3562201797869028","name":"lebatsirhc","avatar":"https://static.tigerbbs.com/3cfcaf13a73e3cf5792c54a3337d2315","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3562201797869028","idStr":"3562201797869028"},"themes":[],"htmlText":"Average down!","listText":"Average down!","text":"Average down!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/367619911","repostId":"2117201682","repostType":4,"isVote":1,"tweetType":1,"viewCount":128,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":367610606,"gmtCreate":1614943314205,"gmtModify":1704777257211,"author":{"id":"3562201797869028","authorId":"3562201797869028","name":"lebatsirhc","avatar":"https://static.tigerbbs.com/3cfcaf13a73e3cf5792c54a3337d2315","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3562201797869028","idStr":"3562201797869028"},"themes":[],"htmlText":"At a loss but holding ","listText":"At a loss but holding ","text":"At a loss but holding","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/367610606","repostId":"1181340207","repostType":4,"isVote":1,"tweetType":1,"viewCount":80,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":367634648,"gmtCreate":1614943129684,"gmtModify":1704777256081,"author":{"id":"3562201797869028","authorId":"3562201797869028","name":"lebatsirhc","avatar":"https://static.tigerbbs.com/3cfcaf13a73e3cf5792c54a3337d2315","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3562201797869028","idStr":"3562201797869028"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/367634648","repostId":"1145536641","repostType":4,"isVote":1,"tweetType":1,"viewCount":104,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":373626144,"gmtCreate":1618843605888,"gmtModify":1704715799233,"author":{"id":"3562201797869028","authorId":"3562201797869028","name":"lebatsirhc","avatar":"https://static.tigerbbs.com/3cfcaf13a73e3cf5792c54a3337d2315","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3562201797869028","authorIdStr":"3562201797869028"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NNDM\">$Nano Dimension(NNDM)$</a>Like if you're still holding","listText":"<a href=\"https://laohu8.com/S/NNDM\">$Nano Dimension(NNDM)$</a>Like if you're still holding","text":"$Nano Dimension(NNDM)$Like if you're still holding","images":[{"img":"https://static.tigerbbs.com/c6eb8290d836873ae5c6ece4cb072279","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":16,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/373626144","isVote":1,"tweetType":1,"viewCount":366,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":199732328,"gmtCreate":1620733316664,"gmtModify":1704347500670,"author":{"id":"3562201797869028","authorId":"3562201797869028","name":"lebatsirhc","avatar":"https://static.tigerbbs.com/3cfcaf13a73e3cf5792c54a3337d2315","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3562201797869028","authorIdStr":"3562201797869028"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>like if you're gonna hold through","listText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>like if you're gonna hold through","text":"$NIO Inc.(NIO)$like if you're gonna hold through","images":[{"img":"https://static.tigerbbs.com/c1c7917136a0ac1b9421f0d6531ab349","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/199732328","isVote":1,"tweetType":1,"viewCount":418,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":362317833,"gmtCreate":1614596688922,"gmtModify":1704772837890,"author":{"id":"3562201797869028","authorId":"3562201797869028","name":"lebatsirhc","avatar":"https://static.tigerbbs.com/3cfcaf13a73e3cf5792c54a3337d2315","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3562201797869028","authorIdStr":"3562201797869028"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/362317833","repostId":"1161169607","repostType":4,"isVote":1,"tweetType":1,"viewCount":42,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":321094765,"gmtCreate":1615383931257,"gmtModify":1704781958076,"author":{"id":"3562201797869028","authorId":"3562201797869028","name":"lebatsirhc","avatar":"https://static.tigerbbs.com/3cfcaf13a73e3cf5792c54a3337d2315","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3562201797869028","authorIdStr":"3562201797869028"},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/SOS\">$SOS Limited(SOS)$</a> Its gonna fly up, hang on tight guys!","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/SOS\">$SOS Limited(SOS)$</a> Its gonna fly up, hang on tight guys!","text":"$SOS Limited(SOS)$ Its gonna fly up, hang on tight guys!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/321094765","isVote":1,"tweetType":1,"viewCount":44,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":329575317,"gmtCreate":1615263962939,"gmtModify":1704780303125,"author":{"id":"3562201797869028","authorId":"3562201797869028","name":"lebatsirhc","avatar":"https://static.tigerbbs.com/3cfcaf13a73e3cf5792c54a3337d2315","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3562201797869028","authorIdStr":"3562201797869028"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>Fundamentals of the company has not changed","listText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>Fundamentals of the company has not changed","text":"$NIO Inc.(NIO)$Fundamentals of the company has not changed","images":[{"img":"https://static.tigerbbs.com/22398505ea945a7866c7a96be600c345","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/329575317","isVote":1,"tweetType":1,"viewCount":51,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":371979638,"gmtCreate":1618906778324,"gmtModify":1704716664186,"author":{"id":"3562201797869028","authorId":"3562201797869028","name":"lebatsirhc","avatar":"https://static.tigerbbs.com/3cfcaf13a73e3cf5792c54a3337d2315","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3562201797869028","authorIdStr":"3562201797869028"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/371979638","repostId":"1143900668","repostType":4,"isVote":1,"tweetType":1,"viewCount":383,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":328227651,"gmtCreate":1615533356073,"gmtModify":1704784190685,"author":{"id":"3562201797869028","authorId":"3562201797869028","name":"lebatsirhc","avatar":"https://static.tigerbbs.com/3cfcaf13a73e3cf5792c54a3337d2315","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3562201797869028","authorIdStr":"3562201797869028"},"themes":[],"htmlText":"Ohh nice","listText":"Ohh nice","text":"Ohh nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/328227651","repostId":"1199156489","repostType":4,"isVote":1,"tweetType":1,"viewCount":39,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":365717568,"gmtCreate":1614780223954,"gmtModify":1704775122674,"author":{"id":"3562201797869028","authorId":"3562201797869028","name":"lebatsirhc","avatar":"https://static.tigerbbs.com/3cfcaf13a73e3cf5792c54a3337d2315","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3562201797869028","authorIdStr":"3562201797869028"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/365717568","repostId":"1150809937","repostType":4,"isVote":1,"tweetType":1,"viewCount":132,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":355732321,"gmtCreate":1617103824263,"gmtModify":1704695855931,"author":{"id":"3562201797869028","authorId":"3562201797869028","name":"lebatsirhc","avatar":"https://static.tigerbbs.com/3cfcaf13a73e3cf5792c54a3337d2315","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3562201797869028","authorIdStr":"3562201797869028"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NNDM\">$Nano Dimension(NNDM)$</a>see you in 5 years","listText":"<a href=\"https://laohu8.com/S/NNDM\">$Nano Dimension(NNDM)$</a>see you in 5 years","text":"$Nano Dimension(NNDM)$see you in 5 years","images":[{"img":"https://static.tigerbbs.com/43cb66f9dc0c223d6dea5581184b5ed6","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/355732321","isVote":1,"tweetType":1,"viewCount":144,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":367619911,"gmtCreate":1614943365033,"gmtModify":1704777258017,"author":{"id":"3562201797869028","authorId":"3562201797869028","name":"lebatsirhc","avatar":"https://static.tigerbbs.com/3cfcaf13a73e3cf5792c54a3337d2315","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3562201797869028","authorIdStr":"3562201797869028"},"themes":[],"htmlText":"Average down!","listText":"Average down!","text":"Average down!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/367619911","repostId":"2117201682","repostType":4,"isVote":1,"tweetType":1,"viewCount":128,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":373335850,"gmtCreate":1618820768670,"gmtModify":1704715331474,"author":{"id":"3562201797869028","authorId":"3562201797869028","name":"lebatsirhc","avatar":"https://static.tigerbbs.com/3cfcaf13a73e3cf5792c54a3337d2315","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3562201797869028","authorIdStr":"3562201797869028"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/373335850","repostId":"1131815435","repostType":4,"isVote":1,"tweetType":1,"viewCount":262,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":367610606,"gmtCreate":1614943314205,"gmtModify":1704777257211,"author":{"id":"3562201797869028","authorId":"3562201797869028","name":"lebatsirhc","avatar":"https://static.tigerbbs.com/3cfcaf13a73e3cf5792c54a3337d2315","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3562201797869028","authorIdStr":"3562201797869028"},"themes":[],"htmlText":"At a loss but holding ","listText":"At a loss but holding ","text":"At a loss but holding","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/367610606","repostId":"1181340207","repostType":4,"isVote":1,"tweetType":1,"viewCount":80,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":376388297,"gmtCreate":1619089745719,"gmtModify":1704719458826,"author":{"id":"3562201797869028","authorId":"3562201797869028","name":"lebatsirhc","avatar":"https://static.tigerbbs.com/3cfcaf13a73e3cf5792c54a3337d2315","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3562201797869028","authorIdStr":"3562201797869028"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/376388297","repostId":"2129938659","repostType":4,"isVote":1,"tweetType":1,"viewCount":389,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":388543088,"gmtCreate":1613065813144,"gmtModify":1704878165471,"author":{"id":"3562201797869028","authorId":"3562201797869028","name":"lebatsirhc","avatar":"https://static.tigerbbs.com/3cfcaf13a73e3cf5792c54a3337d2315","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3562201797869028","authorIdStr":"3562201797869028"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/388543088","repostId":"1168862133","repostType":4,"isVote":1,"tweetType":1,"viewCount":39,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":815597051,"gmtCreate":1630687082573,"gmtModify":1676530377605,"author":{"id":"3562201797869028","authorId":"3562201797869028","name":"lebatsirhc","avatar":"https://static.tigerbbs.com/3cfcaf13a73e3cf5792c54a3337d2315","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3562201797869028","authorIdStr":"3562201797869028"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/815597051","repostId":"2164879370","repostType":4,"isVote":1,"tweetType":1,"viewCount":429,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":810442478,"gmtCreate":1629997599494,"gmtModify":1676530197097,"author":{"id":"3562201797869028","authorId":"3562201797869028","name":"lebatsirhc","avatar":"https://static.tigerbbs.com/3cfcaf13a73e3cf5792c54a3337d2315","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3562201797869028","authorIdStr":"3562201797869028"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/810442478","repostId":"2162931260","repostType":4,"isVote":1,"tweetType":1,"viewCount":479,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":134887062,"gmtCreate":1622215957856,"gmtModify":1704181755331,"author":{"id":"3562201797869028","authorId":"3562201797869028","name":"lebatsirhc","avatar":"https://static.tigerbbs.com/3cfcaf13a73e3cf5792c54a3337d2315","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3562201797869028","authorIdStr":"3562201797869028"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/134887062","repostId":"1170226387","repostType":4,"isVote":1,"tweetType":1,"viewCount":326,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":135364657,"gmtCreate":1622132645479,"gmtModify":1704180143155,"author":{"id":"3562201797869028","authorId":"3562201797869028","name":"lebatsirhc","avatar":"https://static.tigerbbs.com/3cfcaf13a73e3cf5792c54a3337d2315","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3562201797869028","authorIdStr":"3562201797869028"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/135364657","repostId":"2138531112","repostType":4,"isVote":1,"tweetType":1,"viewCount":412,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":106607516,"gmtCreate":1620107296135,"gmtModify":1704338768710,"author":{"id":"3562201797869028","authorId":"3562201797869028","name":"lebatsirhc","avatar":"https://static.tigerbbs.com/3cfcaf13a73e3cf5792c54a3337d2315","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3562201797869028","authorIdStr":"3562201797869028"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/106607516","repostId":"1140379495","repostType":4,"isVote":1,"tweetType":1,"viewCount":202,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":375684433,"gmtCreate":1619333107922,"gmtModify":1704722598125,"author":{"id":"3562201797869028","authorId":"3562201797869028","name":"lebatsirhc","avatar":"https://static.tigerbbs.com/3cfcaf13a73e3cf5792c54a3337d2315","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3562201797869028","authorIdStr":"3562201797869028"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/375684433","repostId":"2129365307","repostType":4,"isVote":1,"tweetType":1,"viewCount":434,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}